

# Virobay


Virobay is a leader in protease inhibitor design. At Virobay we are investigating promising new approaches using protease inhibition for the treatment of auto immune diseases, neuropathic pain, liver disease and cancer.

Founded in 2006 our scientists have applied their extensive knowledge and experience designing selective protease inhibitors to the cathepsin family of proteases. Members of the cathepsin family are implicated as key mediators in the pathology of diseases, including certain autoimmune disorders, neuropathic pain, liver diseases, atherosclerosis, osteoporosis, COPD and cancer. Virobay compounds are highly potent, orally active and drug-like, addressing common problems in the design of cathepsin inhibitors. Virobay's cathepsin inhibitors include compounds that are highly specific for individual cathepsins (e.g., cathepsin S) as well as compounds that are broadly active against multiple cathepsins.

Our management team, based in Menlo Park, California has decades of experience in drug development, including leadership roles at Roche, Wellcome, Sugen and Celera Genomics.

As a virtual company, Virobay in-house expertise is complemented by the extensive resources available at contract facilities world-wide, creating operational flexibility for cost effective and efficient drug discovery and development.

## Our Pipeline



# Virobay's Management Team



**Robert Booth PhD**  
Chief Executive Officer, Virobay

Robert Booth was the driving force behind the creation of Virobay in 2006. Previously, he was Senior Vice President of Research & Development at Celera Genomics, responsible for integrating and leading Celera's therapeutic discovery and development activities.

Robert also served in a series of executive positions at Roche for over 13 years, including Senior Vice President responsible for research and early development of inflammatory, viral, respiratory, and bone disease products.

Robert is a member of the Science Advisory Board of ShangPharma ChemPartner, serves as a consultant to a number of biotech and venture capital groups, and is a board observer with Galleon Pharmaceuticals.

Robert obtained his PhD in biochemistry from the University of London.



**Jeffrey Latts MD**  
Chief Medical Advisor

Jeff Latts has been working with Virobay since 2010 using his extensive knowledge of clinical and preclinical development to guide Virobay's development strategies. Jeff has been a consultant to the pharmaceutical industry since January 2007.

Previously, Jeff served as Executive Vice President of Exelixis, Inc., a biotechnology company, from January 2006 to January 2007, and as Senior Vice President of Exelixis, Inc. from July 2001 to December 2005. He also served as Chief Medical Officer of Exelixis, Inc. from July 2001 to September 2006.

Prior to that, Jeff held key management positions with Berlex Laboratories, a pharmaceutical healthcare company, where he served as Chief medical Officer from 1995 to 2001, and Vice President, Clinical Research and Development from 1990 to 2001. Prior to that, Jeff served as Vice President, Clinical Research at Wyeth Ayerst Research, a division of Wyeth Laboratories. He began his career in the pharmaceutical industry with the Parke-Davis Pharmaceutical Division of Warner Lambert.

Jeff received a B.S. in medicine and an M.D. from the University of Minnesota.



# Virobay's Management Team



**Leslie Holsinger PhD**  
Vice President, Biology

Leslie Holsinger is responsible for biology and translational medicine at Virobay having joined the company from Celera Genomics where she served as Head of Cell Biology.

At Virobay, Leslie is responsible for all of the biology studies associated with our programs, including compound screening, cell biology, and pharmacology studies in preclinical and clinical studies.

Previously, Leslie was a Group Leader in biology at Sugen, where she was involved in drug discovery programs focused on kinase and phosphatase biology in multiple therapeutic areas.

She completed her post-doctoral studies at the Stanford Medical School having earned her PhD in virology from Northwestern University.



**Jeff Dener PhD**  
Senior Director, Chemical Development

Jeff Dener manages many of the strategic partnerships that Virobay has established with leading contract manufacturers around the world, including suppliers in Europe, Asia and North America. He is an expert in the outsourcing of medicinal and process chemistry for therapeutic areas including inflammation, pain, cardiovascular, oncology, and virology.

Before joining Virobay, Jeff was Scientific Fellow at Celera Genomics where he held an active role in both the development of process chemistry for, and management of, contract manufacturing activities for two molecules, which subsequently entered clinical trials. Prior to Celera, he was a key contributor to drug discovery and development programs at Axys Pharmaceuticals, Shaman Pharmaceuticals and Rhône-Poulenc Rorer, now part of Sanofi-Aventis.

Jeff received a BS in Chemistry from Bucknell University and obtained his PhD in Organic Chemistry from The Ohio State University under the direction of Professor David J. Hart. Subsequently, he was a Post-Doctoral Research Associate in the research group of Professor Henry Rapoport at the University of California, Berkeley.



# Board of Directors

---

**Robert Booth PhD**

Chief Executive Officer, Virobay

**Dan Janney MBA**

Managing Director, Alta Partners

**Jeff Bird PhD**

Managing Director, Sutter Hill Ventures

**Heather Preston MD**

Managing Director, TPG Growth Biotech

---

# Investors

**Alta Partners**

**Sutter Hill Ventures**

**TPG**

---

# Contact

Virobay  
1490 O'Brien Drive, Suite G  
Menlo Park, CA 94025

Office: +1(650) 833-5700

Fax: +1(650) 833-6892

Email: [info@virobayinc.com](mailto:info@virobayinc.com)



Discovering the possibilities

